Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...

Occlusion Perfusion Catheter Demonstrates Superior Performance in PAD Drug Delivery Researchers successfully demonstrate the delivery of liquid sirolimus into the arterial wall using the OPC, which can also be used for paclitaxel BTK.

Coronary Stents Market worth $13.87 Billion by 2025 - Exclusive Report by The Insight Partners Pune, India, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Coronary stents are a kind of little mesh metal tubes that are developed for providing support to the weakened arteries within the heart. The coronary...

Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer Novel TKI compound with dual selective targeting of mutant forms of EGFR and BTKMore than 600 patients have been treated with the compound across studies, with over 200 patients in the completed...

ArQule Announces $15.3 Million Registered Direct Offering of Common Stock BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it has entered into definitive agreements with certain institutional and accredited investors to raise...